Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Touloumi, Giota ^a   Pantazis, Nikos ^a   Chaix, Marie Laure ^b   Bucher, Heiner C ^c   Zangerle, Robert ^d   Kran, Anne Marte Bakken ^e   Thiebaut, Rodolphe ^f   Masquelier, Bernard ^g   Kucherer, Claudia ^h   Monforte, Antonella d'Arminio ⁱ   Meyer, Laurence ^j   Porter, Kholoud ^k  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITÉ DE BORDEAUX   (France)

^g HÔPITAL PELLEGRIN   (France)

^h ROBERT KOCH INSTITUTE   (Germany)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^k MRC CLINICAL TRIALS UNIT   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

AFRICAN; ARTICLE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; ETHNIC GROUP; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; SEROCONVERSION; TREATMENT DURATION; VIREMIA;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84880822314     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071174     Document Type: Article

References (32)

1. Sharp PM, Hahn BH, (2010) The evolution of HIV-1 and the origin of AIDS. Philos Trans R Soc Lond B Biol Sci 365: 2487-2494.
2. Geretti AM, (2006) HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 19: 1-7.
3. Tebit DM, Nankya I, Arts EJ, Gao Y, (2007) HIV diversity, recombination and disease progression: how does fitness "fit" into the puzzle? AIDS Rev 9: 75-87.
4. Hemelaar J, Gouws E, Ghys PD, Osmanov S, (2011) Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 25: 679-689.
5. Lal RB, Chakrabarti S, Yang C, (2005) Impact of genetic diversity of HIV-1 on diagnosis, antiretroviral therapy & vaccine development. Indian J Med Res 121: 287-314.
6. Holguin A, Ramirez de Arellano E, Rivas P, Soriano V, (2006) Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev 8: 98-9107.
7. Kantor R, (2006) Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Infect Dis 19: 594-606.
8. de Arellano ER, Benito JM, Soriano V, Lopez M, Holguin A, (2007) Impact of ethnicity and HIV type 1 subtype on response to first-line antiretroviral therapy. AIDS Res Hum Retroviruses 23: 891-894.
9. Frater AJ, Dunn DT, Beardall AJ, Ariyoshi K, Clarke JR, et al. (2002) Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 16: 1139-1146.
10. Bannister WP, Ruiz L, Loveday C, Vella S, Zilmer K, et al. (2006) HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther 11: 707-715.
11. Atlas A, Granath F, Lindstrom A, Lidman K, Lindback S, et al. (2005) Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapy. AIDS Res Hum Retroviruses 21: 221-227.
12. Alexander CS, Montessori V, Wynhoven B, Dong W, Chan K, et al. (2002) Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir Ther 7: 31-35.
13. Bocket L, Cheret A, Deuffic-Burban S, Choisy P, Gerard Y, et al. (2005) Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness. Antivir Ther 10: 247-254.
14. De Wit S, Boulme R, Poll B, Schmit J-C, Clumeck N, (2004) Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients. AIDS 18: 2330-2331.
15. Geretti AM, Harrison L, Green H, Sabin C, Hill T, et al. (2009) Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 48: 1296-1305.
16. Easterbrook PJ, Smith M, Mullen J, O'Shea S, Chrystie I, et al. (2010) Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J Int AIDS Soc 13: 4-4.
17. Lacerda HR, Medeiros LB, Cavalcanti AM, Ximenes RA, Albuquerque Mde F, (2007) Comparison of the epidemiology, profile of mutations, and clinical response to antiretrovirals among subtypes B and F of the human immunodeficiency virus type 1. Mem Inst Oswaldo Cruz 102: 693-699.
18. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, et al. (2008) Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 300: 51-59.
19. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, et al. (2005) An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21: 3797-3800.
20. Aalen O, Johansen S, (1978) An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat 5: 141-150.
21. Kalbfleish JD, Prentice RL (2002) The statistical analysis of failure time data. New York: John Wiley.
22. Scherrer AU, Ledergerber B, von Wyl V, Boni J, Yerly S, et al. (2011) Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis. 53: 1143-1152.
23. Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, et al. (2002) The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis 35: 1541-1548.
24. Descamps D, Chaix M-L, Andre P, Brodard V, Cottalorda J, et al. (2005) French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 38: 545-552.
25. Fox J, Dudaz A, Green H, Dunn D, Kaye S, et al. (2007) Epidemiology of non-B clade forms in MSM in the UK [poster 117]. In: Program and abstracts of the 13th Annual Conference of the British HIV Association. British HIV Association. Edinburgh, Scotland.
26. Gonzalez-Alba JM, Holguin A, Garcia R, Garcia-Bujalance S, Alonso R, et al. (2011) Molecular surveillance of HIV-1 in Madrid, Spain: a phylogeographic analysis. J Virol 85: 10755-10763.
27. Trevino A, Soriano V, Rodriguez C, Arredondo M, Rivas P, et al. (2011) Changing rate of non-B subtypes and coinfection with hepatitis B/C viruses in newly diagnosed HIV type 1 individuals in Spain. AIDS Res Hum Retroviruses 27: 633-638.
28. Giuliani M, Montieri S, Palamara G, Latini A, Alteri C, et al. (2009) Non-B HIV type 1 subtypes among men who have sex with men in Rome, Italy. AIDS Res Hum Retroviruses 25: 157-164.
29. Perrin L, Kaiser L, Yerly S, (2003) Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis 3: 22-27.
30. Tesoriero J, French T, Weiss L, Waters M, Finkelstein R, et al. (2003) Stability of adherence to highly active antiretroviral therapy over time among clients enrolled in the treatment adherence demonstration project. J Acquir Immune Defic Syndr 33: 484-493.
31. Boyd AE, Murad S, O'Shea S, de Ruiter A, Watson C, et al. (2005) Ethnic differences in stage of presentation of adults newly diagnosed with HIV-1 infection in south London. HIV Med 6: 59-65.
32. Staehelin C, Keiser O, Calmy A, Weber R, Elzi L, et al. (2012) Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 59: 79-85.